
# Aviso de Derechos para emisoras del





## **BOLSA MEXICANA DE VALORES, S.A.B DE C.V, INFORMA:**

BOLSA MEXICANA DE VALORES, S.A.B DE C.V, INFORMA:	
FOLIO DE REFERENCIA DEL EVENTO CORPORATIVO	239952
FOLIO DE REFERENCIA INDEVAL	832949C005
TIPO DE MENSAJE	Replace
COMPLETO / INCOMPLETO	COMPLETE
CONFIRMADO / NO CONFIRMADO	CONFIRMED
CLAVE DE COTIZACIÓN	AMED
RAZÓN SOCIAL	AMEDISYS, INC.
SERIE	*
ISIN	US0234361089
MERCADO PRINCIPAL	NASDAQ
TIPO DE EVENTO	MERGER
MANDATORIO / OPCIONAL / VOLUNTARIO	Mandatory
FECHA EFECTOS	15/08/2025
OPCIÓN	1
TIPO	Cash
DEFAULT	true
TRANSACCIÓN	Cash Movement
CREDIT / DEBIT	Credit





FECHA: 15/08/2025

Securities Movement	
Debit	
US0234361089	

#### NOTAS DEL EVENTO CORPORATIVO

#### NOTA

#### 15/08/2025

USNASDAQ Equity Corporate Actions Alert 2025 . 439 Information Regarding the Merger of Amedisys Inc (AMED) At a special meeting held on September 8, 2023 theshareholders of Amedisys Inc (AMED)approved a merger with UnitedHealth Group Incorporated (UNH). The merger closed today, August 14, 2025. The details are as follows. Company Issue. Amedisys Inc Common Stock CUSIP 023436108 Symbol. AMED LastTrading Date. August 14, 2025 Marketplace Effective Date for Suspension. August 15, 2025 Merger Consideration, USD101.00 for each share held. (As on 07 08 2025) US SEC CA 0157Amedisvs, Inc FORM 8.K On August 7, 2025, the U.S. Department of Justice (the DOJ) along with the Attorneys General of Maryland, Illinois, New Jersey, and New York (collectively, the States ) filed a proposedfinal judgment (the Proposed Final Judgment ) with the U.S. DistrictCourt for the District of Maryland(the Court ). The Proposed Final Judgment was agreed to by Amedisys, Inc. (Amedisys) and UnitedHealth Group Incorporated ( UnitedHealth Group ). The Proposed Final Judgmentwould, if approved, resolve the DOJs and the States opposition to thepreviously announced merger transaction (the Merger) contemplated under the Agreement and Plan of Merger, dated June 26, 2023 (as modifiedby the waiver dated December 26, 2024, the Merger Agreement ), by andamong UnitedHealth Group, Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group, and Amedisys. The Proposed Final Judgment would, if approved, require the parties to, among other things, carry out certain divestitureswithin 75 days of the Court s entry of an Asset Preservation Hold Separate Stipulation and Order or within 60 days of receipt of all necessary merger clearances under Indianaand West Virginia law, whichever is later. The Proposed Final Judgment is subject to judicial approval under the Antitrust Procedures and Penalties Act, 15 U.S.C. 16, for thelimited purpose of determining whether the Proposed Final Judgment isin the public interest. Completionof the Merger remains subject to certain conditions to the closing of the transactions contemplated by the Merger Agreement, as specified therein.

(14/10/2024)

On June 26, 2023, Amedisys, Inc., a Delaware corporation ("Amedisys"), UnitedHealth Group Incorporated, a Delaware corporation ("UnitedHealth Group") and Aurora Holdings Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of UnitedHealth Group ("Merger Sub") entered into an Agreement and Plan of Merger (the "Merger Agreement").

## Merger Consideration

Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Amedisys common stock issued and outstanding (excluding shares held by Amedisys as treasury stock or owned by UnitedHealth Group or Merger Sub or any of their respective subsidiaries, in each case, immediately prior to the Effective Time) will be converted into the right to receive USD 101 per share in cash, without interest (the Per Share Merger Consideration and the total amount to be paid, the "Merger Consideration"), less any applicable withholding taxes.

#### Conditions to the Merger

The completion of the Merger is subject to certain conditions, including: (1) the adoption of the Merger Agreement by Amedisys stockholders, (2) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (3) the receipt of other required regulatory approvals, (4) the absence of any order or law that has the effect of enjoining or otherwise prohibiting the completion of the Merger, (5) the expiration or termination of the applicable waiting period under applicable antitrust law without the imposition of a Burdensome Condition (as defined in the Merger Agreement), (6) subject to certain exceptions, the accuracy of the representations and warranties of the other party and (7) performance by each party of its respective obligations under the Merger Agreement.

(05/08/2024)

Amedisys Inc. (Nasdaq: AMED) filed paperwork Friday with the U.S. Securities and Exchange Commission saying it has agreed to

## Aviso de Derechos para emisoras del



FECHA: 15/08/2025

divest "certain" locations to an affiliate of home health and hospice company VitalCaring.

The divestiture was a way for Amedisys to avoid further antitrust concerns from regulators prior to it joining UnitedHealth Group (NYSE: UNH).

UnitedHealth Group's Optum agreed to purchase Amedisys last June for a purchase price of \$3.3 billion. Optum already owns LHC Group, another one of the largest home health companies in the country.